Testing effectiveness (Phase 2)Not Yet RecruitingNCT07124793
What this trial is testing
IBI363 Combination Therapy in Participants With Advanced Solid Tumors
Who this might be right for
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
Innovent Biologics (Suzhou) Co. Ltd. 60